ریبونوکلئازها به عنوان عوامل درمانی بالقوه

آرین­نژاد حمید، نصیری محمدرضا، جوادمنش علی، قوتی شاهرخ، دهقانی حسام، آسوده احمد (1398) طراحی ساختار پروتئینی آنزیم رانپیرناز به عنوان ایمنوتوکسین براساس ریبونوکلئاز پانکراتیک گاوی با استفاده از مطالعات دینامیک و استاتیک مولکولی. پژوهش­های علوم دامی ایران 12، 351-360.

References

Akbari B, Farajnia S, Ahdi Khosroshahi S, Safari F et al. (2017) Immunotoxins in cancer therapy: Review and update. Int Rev Immunol 36, 207-219.

Ardelt W, Ardelt B, Darzynkiewicz Z (2009) Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 625, 181–189.

Ardelt B, Ardelt W, Pozarowski P (2007) Cytostatic and cytotoxic Properties of amphinase: A novel cytotoxic ribonuclease from Rana pipiens oocytes. Cell Cycle 6, 3097-3102.

Ariannejad H, Nassiri MR, Javadmanesh A, Ghovvati S et al. (2019) Designing of protein structural of Ranpirnase based on bovine pancreatic ribonuclease with using molecular dynamic and static simulation. Iranian J Anim Sci Res 12, 351-360 (In Persian).

Arnold U, Ulbrich HR (2006) Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 28, 1615-1622.

Baranzini N, De Vito A, Orlandi VT, Reguzzoni M et al. (2020) Antimicrobial role of RNASET2 protein during innate immune response in the medicinal leech hirudo verbana. Front Immunol 11, 370.

Benito A, Ribo M, Vilanova M (2005) On the track of antitumour ribonucleases. Mol BioSyst 1, 294-302.

Boix E, Acquati F, Leonidas D, Pulido D (2020) Editorial: Role of Ribonucleases in immune response regulation during infection and cancer. Front Immunol 11, 236.

Bosch M, Benito A, Ribo M (2004) A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity. Biochem 24, 2167-2177.

Bracale A, Castaldi F, Nitsch L, D’Alessio G (2003) A role for the intersubunit disulfides of seminal RNase in the mechanism of its antitumor action. Eur J Biochm 270, 1980-1987.

Burnysheva KM, Petrushanko IY, Spirin PV (2016) Ribonuclease binase induces death in T-cell acute lymphoblastic leukemia cells by apoptosis. Mol Biol 50, 302-306.

Cruz E, Kayser V (2019) Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics 13, 33-51.

Cuchillo CM, Nogués MV, Raines RT (2011) Bovine pancreatic ribonuclease: fifty years of the first enzymatic reaction mechanism. Biochemistry 50, 7835-7841.

Danishefsky SJ, Shue YK, Chang MN, Wong CH (2014) Development of Globo‑H cancer vaccine. ACC Chem Res 48, 643-652.

De Lorenzo C, Arciello A, Cozzolino R, Palmer DB et al. (2004) A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 64, 4870-4874.

Dickson KA, Haigis MC, Raines RT (2005) Ribonuclease inhibitor: Structure and function. Prog Nucleic Acid Res Mol Biol 80, 349–374.

Eller CH, Chao TY, Singarapu KK, Ouerfelli O (2015) Human cancer antigen Globo H is a cell-surface ligand for human Ribonuclease 1. ACS Cent Sci 1,181-190.

Esposito L, Donnarumma F, Ruggiero A, Leone S et al. (2019) Structure, stability and aggregation propensity of a Ribonuclease A-Onconase chimera. Int J Biol Macromol 133, 1125-1133.

Findlay D, Herries DG, Mathias AP, Rabin BR et al. (1961) The active site and mechanism of action of bovine pancreatic ribonuclease. Nature 190, 781–784.

Formoso E, Matxain JM, Lopez X (2010) Molecular dynamics simulation of bovine pancreatic ribonuclease A - CpA and transition state-like complexes. J Phys Chem 114, 7371–7382.

Forouharmehr A, Nassiri MR, Ghovvati Roudsari S, Javadmanesh A (2020) Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines. J Cell Physio 235, 4679-4687.

Ghosh SC, Neslihan Alpay S, Klostergaard J (2012) CD44: A validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets 16, 635–650.

Gotte G, Laurents DV, Merlino A, Picone D et al. (2013) Structural and functional relationships of natural and artificial dimeric bovine ribonucleases: new scaffolds for potential antitumor drugs. FEBS Lett 587, 3601-3608.

Gotte G, Menegazzi M (2019) Biological activities of secretory RNases: Focus on their oligomerization to design antitumor drugs. Front Immunol 10, 2626.

Graça VC, Silva MS, Reis LV, Sousa F et al. (2014) Ethylenediamine-Derived Chromatographic Ligand to Separate BSA, Lysozyme, and RNase A. Chromatographia 77, 1529–1537.

Guillem P, Jiarui L, Fatima A, Helena L et al. (2019) Testing a human antimicrobial RNase chimera against bacterial resistance. Frontiers in Microbiology 10, 1357.

Haigis MC, Kurten EL, Abel RL, Raines RT (2002) KFERQ sequence in ribonuclease A-mediated cytotoxicity. J Biol Chem 277, 11576 -11581.

Haigis MC, Raines RT (2003) Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J Cell Sci 116, 313-24.

Jordaan S, Akinrinmade OA, Nachreiner T, Cremer C et al. (2018) Updates in the development of immunoRNases for the selective killing of tumor cells. Biomedicines 6, 28.

Kanwar SS, Kumar R (2017) Ribonuclease as Anticancer Therapeutics. Enz Eng 6, 162.

Kanwar SS, Mishra P, Meena KR (2016) Ribonucleases and their applications. J Adv Biotechnol Bioeng 4, 17-26.

Kobe B, Deisenhofer J (1996) Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. J Mol Biol 264, 1028-1043.

Lee SY, Kang MS, Jeong WY, Han DW et al. (2020) Hyaluronic acid-based theranostic nanomedicines for targeted cancer therapy. Cancers 12, 940.

Lee HH, Wang YN, Hung MC (2019) Functional roles of the human ribonuclease A superfamily in RNA metabolism and membrane receptor biology. Mol Aspects Med 70, 106–16.

Leich F, Koditz J, Ulbrich-Hofman R, Arnold U (2006) Tandemization endows bovine pancreatic ribonuclease with cytotoxic activity. J Mol Biol 358, 1305–1313.

Liu M, Gou F (2018) Recent updates on cancer immunotherapy. Precis Clin Med 1, 65–74.

Lomax JE, Bianchetti CM, Chang A, Phillips GN et al. (2014) Functional evolution of ribonuclease inhibitor: Insights from birds and reptiles. J Mol Biol 426, 3041–3056.

Makarov AA, Kolchinsky A, Ilinskaya ON (2008) Binase and other microbial RNases as potential anticancer agents. Bioessays 30, 781-90.

Mitkevich VA, Makarov AA, Ilinskaya ON (2014) Cell targets of antitumor ribonucleases. Mol Bio 48, 181-188.

Mohammadabadi MR, Mozafari MR (2019) Enhanced efficacy and bioavailability of thymoquinone using nanoliposomal dosage form. J Drug Delivery Sci Technol 47, 445–453.

Olmo N, Turnay J, Buitrago GG (2001) Cytotoxic mechanism of the ribotoxin-sarcin induction of cell death via apoptosis. Eur J Biochem 268, 2113-2123.

Olombrada M, Lazaro-Gorines R, Lopez-Rodriguez JC (2017) Fungal ribotoxins: A review of potential biotechnological applications. Toxins (Basel. 9, 71.

Pochechueva T, Alam S, Schötzau A, Chinarev A et al. (2017) Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients. J Ovarian Res 10, 8.

Pouckova P, Skvor J, Gotte G, Vottariello F et al. (2006) Some biological actions of PEG-conjugated RNase A oligomers. Neoplasma 53, 79–85.

Riccio G, D’Avino C, Raines RT, De Lorenzo C (2013) A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor. Protein Eng Des Sel 26, 243–248.

Roiz L, Smirnoff P, Bar-Eli M, Schwartz B et al. (2006) ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics. Cancer 106, 2295–308.

Saxena A, Saxena SK, Shogen K (2009) Effect of Onconase on double-stranded RNA in vitro. Anticancer Res 29, 1067-71.

Schwartz B, Shoseyov O, Melnikova VO, McCarty M et al. (2007) Cancer Research 67, 5258-5266.

Suhasini AN, Sirdeshmukh R (2006) Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem 281, 12201-12209.

Suhasini AN, Sirdeshmukh R (2007) Onconase action on tRNA (Lys3), the primer for HIV-1 reverse transcription. Biophys Res Commun 363, 304-309.

Shruti G, Sukhdev S, Shamsher K (2016) An overview on ribonuclease and their therapeutic effects. Insight Med 1, 1-11.

Suri S, Panda B, Javed S, Mohd A (2007) RNase: A novel enzyme for treatment of cancers. Internet J Oncol 5, 1-5.

Wang X, Li Y, Li Q (2017) Hyaluronic acid modification of RNase and its intracellular delivery using lipid-like nanoparticles. J Control Release 263, 39-45.

Wang Z, Tang Y, Xie L, Huang A et al. (2019) The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis. Front. Oncol. 9, 309.

Wu L, Xu Y, Zhao H, Li Y (2020) RNase T2 in inflammation and cancer: Immunological and biological views. Front. Immunol 11, 1554.

Yuki S, Kondo Y, Kato F (2004) Noncytotoxic ribonuclease, RNase T1, induces tumor cell death via hemagglutinating virus of Japan envelope vector. Eur J Biochem 271, 3567-72.

Zhang H, Chen J (2018) Current status and future directions of cancer immunotherapy. J Cancer 9, 1773–1781.